PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 155 filers reported holding PROGENICS PHARMACEUTICALS IN in Q1 2018. The put-call ratio across all filers is 0.92 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $413,000 | +103.4% | 55,300 | +61.7% | 0.01% | +150.0% |
| Q4 2017 | $203,000 | -25.4% | 34,200 | -7.3% | 0.00% | -33.3% |
| Q3 2017 | $272,000 | -11.1% | 36,900 | -18.2% | 0.00% | -25.0% |
| Q2 2017 | $306,000 | +18.1% | 45,100 | +64.6% | 0.00% | +33.3% |
| Q1 2017 | $259,000 | +488.6% | 27,400 | +163.5% | 0.00% | +200.0% |
| Q2 2016 | $44,000 | -84.9% | 10,400 | -78.2% | 0.00% | -75.0% |
| Q4 2015 | $292,000 | +87.2% | 47,600 | +74.4% | 0.00% | +100.0% |
| Q3 2015 | $156,000 | – | 27,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 8,951,169 | $54,871,000 | 3.38% |
| Virtus ETF Advisers LLC | 103,807 | $636,000 | 1.75% |
| BKS ADVISORS, LLC | 291,150 | $1,785,000 | 0.92% |
| Piermont Capital Management Inc. | 363,549 | $2,229,000 | 0.71% |
| TUDOR INVESTMENT CORP ET AL | 2,370,760 | $14,532,000 | 0.41% |
| SEARLE & CO. | 60,000 | $349,000 | 0.34% |
| TURNER INVESTMENTS LLC | 252,785 | $1,550,000 | 0.32% |
| RICE HALL JAMES & ASSOCIATES, LLC | 891,672 | $5,466,000 | 0.31% |
| Phocas Financial Corp. | 635,333 | $3,895,000 | 0.30% |
| TFS CAPITAL LLC | 398,283 | $2,441,000 | 0.26% |